Sernova closes $874,600 first tranche of placement

Executive Summary

• Sernova Biotherapeutics closed the first tranche of a private placement, raising $874,600 in gross proceeds from existing and new investors.
• The company aims to raise up to $5 million in total, with proceeds designated for general operating capital and the launch of the final Cohort C in its Phase 1/2 clinical trial for Type 1 diabetes (T1D).
• The financing includes the issuance of 5,466,250 units at 16 cents per unit, each comprising one common share and one warrant exercisable at 40 cents for 36 months.

Key Details

• Gross Proceeds: $874,600 raised in the first tranche; target total raise is up to $5 million.
• Units Issued: 5,466,250 units.
• Price Per Unit: 16 cents.
• Warrant Terms: Each unit includes one warrant with an exercise price of 40 cents, exercisable for 36 months.
• Use of Proceeds: General operating capital and launch of the final Cohort C in the Phase 1/2 clinical trial evaluating the proprietary cell pouch biohybrid organ for T1D treatment.
• Clinical Update: Cohort C will incorporate tegoprubart, a novel investigational immunomodulatory antibody, replacing the current standard of care tacrolimus. The company anticipates improved clinical outcomes regarding insulin-producing islet cell engraftment, survival, and function.
• Additional Financing: The company is pursuing non-dilutive financing to further support the clinical program.
• Debt Conversion: The CEO noted a previously announced settlement conversion of $13.8 million of legacy debt to equity, which strengthens the balance sheet.
• Regulatory Conditions: Completion is subject to customary closing conditions, including acceptance by the Toronto Stock Exchange.
• Hold Period: All securities are subject to a statutory hold period of four months.

Notable Quotes

• "This financing and the anticipated subsequent tranches plus a further increase in the previously announced settlement conversion of $13.8-million of legacy debt to equity significantly strengthens our balance sheet as we enter an exciting new phase of clinical development," said Jonathan Rigby, chief executive officer of Sernova.
• "With the launch of Cohort C, which will incorporate tegoprubart, we are building on promising clinical results to further optimize patient outcomes and move closer to a functional cure for insulin-dependent diabetes."